Myotonic Dystrophy 1 Clinical Trial
Official title:
Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study
Verified date | April 2016 |
Source | University Hospital, Bonn |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ministry of Health |
Study type | Observational |
The natural history of brain affection in myotonic dystrophy types 1 and 2 is still unknown. The investigators designed a 5-year longitudinal neuropsychological and neuroimaging follow-up study to address this issue. Myotonic dystrophy type 1, myotonic dystrophy type 2 patients, and healthy controls were enrolled. All participants undergo clinical-neurological examinations, neuropsychological analyses according to a 13-item neuropsychological test battery, and 3T-brain MRI including voxel-based morphometry and diffusion tensor imaging at baseline and at follow-up using identical examination protocols.
Status | Completed |
Enrollment | 49 |
Est. completion date | August 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion criteria for healthy controls: - written informed consent - normal neurological examination without any acute or former neurological or severe psychiatric disease, no medical history of traumatic brain injury Inclusion criteria for patients: - written informed consent - diagnosis confirmed by genetic testing - no other neurological or severe psychiatric disease, no medical history of traumatic brain injury Exclusion criteria for healthy controls and patients: - use of psychoactive substances including alcohol (except nicotine), formerly or currently; treatment with modafinil - severe psychiatric disorders, serious physical illnesses, particularly cardiovascular diseases, formerly or currently - non-removable ferromagnetic metallic implants, sensors, stimulators, prostheses, pacemaker, large tattoos - claustrophobia - age under 18 years |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bonn | Forschungszentrum Juelich, Life and Brain Center Bonn, The Marigold Foundation |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in diffusivity indices as assessed by brain MRI with diffusion tensor imaging (DTI) sequences | First analysis at baseline and after 5 years at follow-up | No | |
Primary | Gray matter changes assessed by magnetic resonance imaging (MRI)-voxel-based morphometry (VBM) | First analysis at baseline and after 5 years at follow-up | No | |
Primary | Quantification of white matter lesions using age-related white matter changes (ARWMC) rating scale | First analysis at baseline and after 5 years at follow-up | No | |
Secondary | MIRS (Muscular impairment rating scale) | Rating scale to assess disease severity in myotonic dystrophy type 1 patients | First analysis at baseline and after 5 years at follow-up | No |
Secondary | Motor performance (Purdue Pegboard, bimanual) | A bimanual task to assess fine motor function in patients and controls. Results are used as a covariate for neuropsychological tests | First analysis at baseline and after 5 years at follow-up | No |
Secondary | Beck Depression Inventory (BDI) | To assess depressive symptoms | First analysis at baseline and after 5 years at follow-up | No |
Secondary | Boston Naming Test | A test to evaluate semantic memory. | First analysis at baseline and after 5 years at follow-up | No |
Secondary | Verbal memory recognition task, a subtest of a computerised neuropsychological screening test battery, named NeuroCogFX (Fliessbach et al., 2006). | Word list learning: 3 repetitions of word list presentation, 12 words. Yes/No recognition test (items:distractors 1 : 2) (reaction intervall: 2 seconds). Data measurement: reaction time, number of correct hits |
First analysis at baseline and after 5 years at follow-up | No |
Secondary | Figural memory recognition task, a subtest of a computerised neuropsychological screening test battery, named NeuroCogFX (Fliessbach et al., 2006). | Figural pattern learning: 12 different checkerboard patterns are presented, 3 repetitions of checkboard pattern presentation. Checkerboard consists of 3x3 fields, each pattern consists of 4 highlighted fields. Yes/No recognition test (items:distractors 1 : 2) (reaction interval: 2 seconds). Data measurement: reaction time, number of correct hits |
First analysis at baseline and after 5 years at follow-up | No |
Secondary | Focussed Attention. Focussed attention concerning processing speed is assessed with a symbol-counting task (subtest 1 of the "Cerebraler Insuffizienztest", c.I.T.S. (Lehrl, 1997)). | Data measurement: time | First analysis at baseline and after 5 years at follow-up | No |
Secondary | Psychomotoric Speed. Psychomotoric speed is assessed using the Trail-Making Test, TMT A (Reitan, 1958). | The TMT-A test consists of 25 numbered circles randomly distributed over a sheet of paper. The study participant needs to draw lines to connect the numbers in ascending order. Data measurement: time |
First analysis at baseline and after 5 years at follow-up | No |
Secondary | Reaction time, a subtest of a computerised neuropsychological screening test battery, named NeuroCogFX (Fliessbach et al., 2006). | Data measurement: time | First analysis at baseline and after 5 years at follow-up | No |
Secondary | Selective attention (Choice reaction time), a subtest of a computerised neuropsychological screening test battery, named NeuroCogFX (Fliessbach et al., 2006). | Data measurement: time | First analysis at baseline and after 5 years at follow-up | No |
Secondary | Interference. Interference is analysed using two tasks. | Response inhibition subtest of the "Cerebraler Insuffizienztest" (c.I.T.I; Lehrl and Fischer, 1997). Inverted choice reaction with reversed conditions of a choice reaction task, a subtest of a computerised neuropsychological screening test battery, named NeuroCogFX (Fliessbach et al., 2006). Data measurement: reaction time |
First analysis at baseline and after 5 years at follow-up | No |
Secondary | Attention shift. Attentional shift is analysed using the the Trail-Making Test, TMT B (Reitan, 1958). | The TMT B test consists of 25 circles randomly distributed over a sheet of paper. These circles include both numbers and letters. The study participant needs to draw lines to connect the numbers and letters in an ascending order, but alternating between numbers and letters. Data measurement: time |
First analysis at baseline and after 5 years at follow-up | No |
Secondary | Visual-spatial / visual-constructive abilities. Visual-spatial / visual-constructive abilities are investigated using the Block design Test (part of "Hamburg-Wechsler Intelligenztest für Erwachsene"—Revision (HAWIE-R); Tewes, 1991). | The block design test consists of 9 blocks and 9 pictures. The study participant needs to look at the picture and reconstruct each picture by arranging all 9 blocks. Data measurement: time |
First analysis at baseline and after 5 years at follow-up | No |
Secondary | Phonematic fluency. Phonemic verbal word fluency is assessed using the oral word-fluency test, subtest 6 of the "Leistungsprüfsystem"; Horn, 1983. | In a given time (one minute) the study participant needs to list as many words that begin with a certain letter. Data measurement: number of correct words |
First analysis at baseline and after 5 years at follow-up | No |
Secondary | Semantic fluency. Semantic word fluency is assessed using a test by Strauss et al.,2006. | A certain category is provided and in a given time (one minute) the study participant needs to list as many items belonging to that category. Data measurement: number of correct items |
First analysis at baseline and after 5 years at follow-up | No |
Secondary | Daytime Sleepiness Scale (DSS) | First analysis at baseline and after 5 years at follow-up | No | |
Secondary | Krupp's Fatigue Severity Scale (KFSS) | First analysis at baseline and after 5 years at follow-up | No | |
Secondary | Epworth Sleepiness Scale (ESS) | First analysis at baseline and after 5 years at follow-up | No | |
Secondary | Pittsburgh Sleep Quality Index (PSQI) | First analysis at baseline and after 5 years at follow-up | No | |
Secondary | Ullanlinna-Narcolepsy Scale (UNS) | First analysis at baseline and after 5 years at follow-up | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02880735 -
Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy
|
N/A | |
Recruiting |
NCT06378216 -
Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]
|
||
Active, not recruiting |
NCT06089018 -
Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy
|
||
Completed |
NCT05662150 -
Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1
|
N/A | |
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Completed |
NCT05027269 -
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04712422 -
Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
|
||
Recruiting |
NCT05006924 -
Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1
|
||
Recruiting |
NCT04656210 -
Myotonic Dystrophy - Vascular and Cognition
|
||
Completed |
NCT04634682 -
Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1
|
N/A | |
Withdrawn |
NCT06270186 -
Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach
|
N/A | |
Recruiting |
NCT06411288 -
Global Study of Del-desiran for the Treatment of DM1
|
Phase 3 | |
Recruiting |
NCT06300307 -
Study of ATX-01 in Participants With DM1
|
Phase 1/Phase 2 | |
Recruiting |
NCT06138743 -
Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
|
Phase 1 | |
Not yet recruiting |
NCT05532813 -
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
|
Phase 3 | |
Active, not recruiting |
NCT04886518 -
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
|
Phase 2 | |
Completed |
NCT05036447 -
Myotonic Dystrophy Type 1 and Resistance Exercise
|
N/A | |
Recruiting |
NCT03424460 -
Venous Thromboembolism in Myotonic Dystrophy Type 1
|
N/A | |
Recruiting |
NCT05865483 -
Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
|
||
Completed |
NCT04001920 -
Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1
|
N/A |